Crucell Doubles Production of Quinvaxem in 2008 and Prepares Move to New Korean Production Site to Facilitate Growth

24-Oct-2008 - Korea, Republic of (South Korea)

Crucell N.V. announced that an agreement was reached to relocate Crucell's Korean production facility, where its pentavalent children's vaccine Quinvaxem® and a hepatitis B vaccine Hepavax-Gene® are produced, from the Shingal site in Yongin City, Korea to the Incheon Free Economic Zone.

All parties involved have agreed on the time line and conditions of this relocation, enabling a smooth transition to the new production facility. With engineering well underway, construction activities at the new site are due to start soon. The new facility will enable the further growth and efficient production of Quinvaxem® and Hepavax-Gene®. No further details were provided.

"We are pleased that we were able to settle all litigation around our production facility amicably, on terms beneficiary to all parties. Production of Quinvaxem® at our existing site in Shingal has already doubled compared to last year, and the new production facility will support the expected growth of our flagship products in the years to come." said Cees de Jong, Chief Operating Officer of Crucell.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances